AnaptysBio Named a 2013 "Fierce 15" Winner

SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced its selection by the editors of FierceBiotech as one of the Fierce 15 for 2013.   This selection designates AnaptysBio as one of the most promising private companies in the biotechnology industry, and is based upon the Company's validated antibody technology platform, novel therapeutic pipeline, proven leadership team and marquee pharma partnerships. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

"AnaptysBio has attracted some of the best collaboration partners in the business with an innovative approach to developing therapeutic antibodies," says John Carroll, the editor of FierceBiotech. "The Company has leveraged its technology to develop a brand new take on PD-1, one of the hottest fields in R&D today."

"We are delighted to have been selected for this prestigious award and would like to thank the expert editorial team at FierceBiotech for their thoughtful review," said Hamza Suria, president & chief executive officer of AnaptysBio. "Our team continues to succeed in the rapid development of potent antibodies against emerging therapeutic targets.  Coupling our antibody discovery engine with novel target biology has enabled AnaptysBio to develop a strong preclinical pipeline in cancer immunotherapy, pustular psoriasis, atopic dermatitis, fibrosis and other unmet medical needs." 

This year marks FierceBiotech's eleventh Fierce 15 selection, which is an annual award that celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.  A complete list of "Fierce 15" companies is available online at FierceBiotech.com.

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About AnaptysBio

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. We are developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's proprietary SHM-XEL™ platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, stability, function, cross-reactivity, epitope diversity and manufacturability. The Company has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, DARPA and DTRA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit www.anaptysbio.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signing up is free.

Contacts:
Julie Rathbun
[email protected]
206-769-9219

SOURCE AnaptysBio, Inc.